Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional mRNA-2752 and Pembrolizumab in High-Risk DCIS
NCT02872025Phase 1Active, not recruiting
- Sponsor
- Laura Esserman
- Start
- Dec 2016
- Primary completion
- Mar 2026
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mRNA-2752 in ductal carcinoma in situ (DCIS) (6 arms), sponsored by Laura Esserman. Primary endpoints: Maximum Tolerated Dose at 18 months, Dose-limiting toxicities at 18 months and 1 more. Started Dec 2016; status: active, not recruiting.
02
Drugs
mRNA-2752
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT02872025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872025.